The_DT
use_NN
of_IN
glucocorticoids_NNS
in_IN
acute_JJ
lymphoblastic_JJ
leukemia_NN
of_IN
childhood_NN
._.

Molecular_JJ
,_,
cellular_JJ
,_,
and_CC
clinical_JJ
considerations_NNS
._.

Glucocorticoids_NNS
have_VBP
been_VBN
included_VBN
in_IN
almost_RB
all_DT
treatment_NN
regimens_NNS
for_IN
childhood_NN
acute_JJ
lymphoblastic_JJ
leukemia_NN
for_IN
decades_NNS
._.

However_RB
,_,
optimal_JJ
agents_NNS
,_,
doses_NNS
,_,
and\/or_CC
schedules_NNS
have_VBP
yet_RB
to_TO
be_VB
defined_VBN
despite_IN
extensive_JJ
clinical_JJ
application_NN
._.

New_JJ
data_NNS
on_IN
the_DT
pharmacokinetics_NNS
,_,
pharmacodynamics_NNS
,_,
and_CC
molecular_JJ
mechanisms_NNS
of_IN
action_NN
of_IN
glucocorticoids_NNS
have_VBP
suggested_VBN
alternative_JJ
approaches_NNS
in_IN
ALL_NN
._.

These_DT
suggest_VBP
that_IN
prolonged_JJ
,_,
i.e._FW
28_CD
day_NN
,_,
glucocorticoid_NN
therapy_NN
may_MD
be_VB
unnecessary_JJ
as_IN
exposure_NN
to_TO
glucocorticoid_NN
induces_VBZ
down-regulation_NN
of_IN
glucocorticoid_NN
receptors_NNS
._.

Dexamethasone_NN
may_MD
be_VB
superior_JJ
to_TO
prednisone_NN
in_IN
conventional_JJ
equi-effective_NN
doses_NNS
._.

Blast_NN
sensitivity_NN
to_TO
glucocorticoids_NNS
correlates_VBZ
closely_RB
with_IN
sensitivity_NN
to_TO
other_JJ
,_,
putatively_RB
non-cross-resisting_JJ
agents_NNS
and_CC
with_IN
outcome_NN
after_IN
multi-agent_JJ
therapy_NN
,_,
suggesting_VBG
overlapping_VBG
mechanisms_NNS
of_IN
action_NN
,_,
and_CC
focusing_VBG
attention_NN
on_IN
the_DT
determinants_NNS
of_IN
the_DT
threshold_NN
for_IN
apoptosis_NN
._.

Increasing_VBG
success_NN
in_IN
the_DT
treatment_NN
of_IN
childhood_NN
acute_JJ
lymphoblastic_JJ
leukemia_NN
has_VBZ
led_VBN
to_TO
increasing_VBG
awareness_NN
of_IN
avascular_JJ
necrosis_NN
of_IN
bone_NN
as_IN
a_DT
potentially_RB
disabling_VBG
sequela_NN
of_IN
glucocorticoid_NN
therapy_NN
,_,
especially_RB
in_IN
adolescent_JJ
and_CC
young_JJ
adult_JJ
patients_NNS
._.

